Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 117

1.

Patients' perceptions and patient-reported outcomes in progressive-fibrosing interstitial lung diseases.

Swigris JJ, Brown KK, Abdulqawi R, Buch K, Dilling DF, Koschel D, Thavarajah K, Tomic R, Inoue Y.

Eur Respir Rev. 2018 Dec 21;27(150). pii: 180075. doi: 10.1183/16000617.0075-2018. Print 2018 Dec 31. Review.

2.

Optimizing Home Oxygen Therapy. An Official American Thoracic Society Workshop Report.

Jacobs SS, Lederer DJ, Garvey CM, Hernandez C, Lindell KO, McLaughlin S, Schneidman AM, Casaburi R, Chang V, Cosgrove GP, Devitt L, Erickson KL, Ewart GW, Giordano SP, Harbaugh M, Kallstrom TJ, Kroner K, Krishnan JA, Lamberti JP, Porte P, Prieto-Centurion V, Sherman SE, Sullivan JL, Sward E, Swigris JJ, Upson DJ.

Ann Am Thorac Soc. 2018 Dec;15(12):1369-1381. doi: 10.1513/AnnalsATS.201809-627WS.

PMID:
30499721
3.

A New Tool to Capture Patients' Perceptions of the Effects of Lung Transplantation.

Swigris JJ.

Am J Respir Crit Care Med. 2018 Nov 20. doi: 10.1164/rccm.201810-2001ED. [Epub ahead of print] No abstract available.

PMID:
30457877
4.

Rheumatoid Arthritis-Interstitial Lung Disease in the United States: Prevalence, Incidence, and Healthcare Costs and Mortality.

Raimundo K, Solomon JJ, Olson AL, Kong AM, Cole AL, Fischer A, Swigris JJ.

J Rheumatol. 2018 Nov 15. pii: jrheum.171315. doi: 10.3899/jrheum.171315. [Epub ahead of print]

5.

Towards a refined definition of combined pulmonary fibrosis and emphysema.

Swigris JJ.

Respirology. 2019 Jan;24(1):9-10. doi: 10.1111/resp.13426. Epub 2018 Oct 15. No abstract available.

6.

A Patient-Centered Approach to Care and Research in Chronic Disease.

Swigris JJ.

Am J Med Sci. 2018 Aug 21. pii: S0002-9629(18)30307-0. doi: 10.1016/j.amjms.2018.08.008. [Epub ahead of print] No abstract available.

PMID:
30278878
7.

Minimal Important Difference for Physical Activity and Validity of the International Physical Activity Questionnaire in Interstitial Lung Disease.

Hur SA, Guler SA, Khalil N, Camp PG, Guenette JA, Swigris JJ, Ryerson CJ.

Ann Am Thorac Soc. 2019 Jan;16(1):107-115. doi: 10.1513/AnnalsATS.201804-265OC.

PMID:
30211616
8.

Quantitative high-resolution computed tomography fibrosis score: performance characteristics in idiopathic pulmonary fibrosis.

Humphries SM, Swigris JJ, Brown KK, Strand M, Gong Q, Sundy JS, Raghu G, Schwarz MI, Flaherty KR, Sood R, O'Riordan TG, Lynch DA.

Eur Respir J. 2018 Sep 17;52(3). pii: 1801384. doi: 10.1183/13993003.01384-2018. Print 2018 Sep.

PMID:
30139770
9.

Dose modification and dose intensity during treatment with pirfenidone: analysis of pooled data from three multinational phase III trials.

Nathan SD, Lancaster LH, Albera C, Glassberg MK, Swigris JJ, Gilberg F, Kirchgaessler KU, Limb SL, Petzinger U, Noble PW.

BMJ Open Respir Res. 2018 Aug 2;5(1):e000323. doi: 10.1136/bmjresp-2018-000323. eCollection 2018.

10.

Identifying Barriers to Idiopathic Pulmonary Fibrosis Treatment: A Survey of Patient and Physician Views.

Maher TM, Swigris JJ, Kreuter M, Wijsenbeek M, Cassidy N, Ireland L, Axmann J, Nathan SD.

Respiration. 2018;96(6):514-524. doi: 10.1159/000490667. Epub 2018 Aug 16.

PMID:
30114692
11.

Transitions and touchpoints in idiopathic pulmonary fibrosis.

Swigris JJ.

BMJ Open Respir Res. 2018 Jun 29;5(1):e000317. doi: 10.1136/bmjresp-2018-000317. eCollection 2018.

12.

Psychometric properties of the St George's Respiratory Questionnaire in patients with idiopathic pulmonary fibrosis: insights from the INPULSIS trials.

Swigris JJ, Wilson H, Esser D, Conoscenti CS, Stansen W, Kline Leidy N, Brown KK.

BMJ Open Respir Res. 2018 May 18;5(1):e000278. doi: 10.1136/bmjresp-2018-000278. eCollection 2018.

13.

The impact of carrying supplemental oxygen on exercise capacity and dyspnea in patients with interstitial lung disease.

Ramadurai D, Riordan M, Graney B, Churney T, Olson AL, Swigris JJ.

Respir Med. 2018 May;138:32-37. doi: 10.1016/j.rmed.2018.03.025. Epub 2018 Mar 26.

PMID:
29724390
14.

Differentiating Usual Interstitial Pneumonia From Nonspecific Interstitial Pneumonia Using High-resolution Computed Tomography: The "Straight-edge Sign".

Zhan X, Koelsch T, Montner SM, Zhu A, Vij R, Swigris JJ, Chung JH.

J Thorac Imaging. 2018 Jul;33(4):266-270. doi: 10.1097/RTI.0000000000000328.

PMID:
29683868
15.

Pseudoneutropenia in lymphangioleiomyomatosis (LAM) patients receiving sirolimus: evaluation in a 100 patient cohort.

Gopalakrishnan V, Jones AM, Julien-Williams P, Machado T, Danner RL, Swigris JJ, Paine R 3rd, Lozier JN, Moss J.

ERJ Open Res. 2018 Mar 20;4(1). pii: 00121-2017. doi: 10.1183/23120541.00121-2017. eCollection 2018 Jan.

16.

Performance of the St George's Respiratory Questionnaire in patients with connective tissue disease-associated interstitial lung disease.

Suzuki A, Kondoh Y, Swigris JJ, Ando M, Kimura T, Kataoka K, Yamano Y, Furukawa T, Numata M, Sakamoto K, Hasegawa Y.

Respirology. 2018 Mar 25. doi: 10.1111/resp.13293. [Epub ahead of print]

PMID:
29575410
17.

Understanding the informational needs of patients with IPF and their caregivers: 'You get diagnosed, and you ask this question right away, what does this mean?'

Ramadurai D, Corder S, Churney T, Graney B, Harshman A, Meadows S, Swigris JJ.

BMJ Open Qual. 2018 Jan 30;7(1):e000207. doi: 10.1136/bmjoq-2017-000207. eCollection 2018.

18.

Physical activity and activity space in patients with pulmonary fibrosis not prescribed supplemental oxygen.

Root ED, Graney B, Baird S, Churney T, Fier K, Korn M, McCormic M, Sprunger D, Vierzba T, Wamboldt FS, Swigris JJ.

BMC Pulm Med. 2017 Nov 23;17(1):154. doi: 10.1186/s12890-017-0495-2.

19.

Tracking dyspnea up to supplemental oxygen prescription among patients with pulmonary fibrosis.

Olson AL, Graney B, Baird S, Churney T, Fier K, Korn M, McCormick M, Sprunger D, Vierzba T, Wamboldt FS, Swigris JJ.

BMC Pulm Med. 2017 Nov 22;17(1):152. doi: 10.1186/s12890-017-0497-0.

20.

All-cause Healthcare Costs and Mortality in Patients with Systemic Sclerosis with Lung Involvement.

Fischer A, Kong AM, Swigris JJ, Cole AL, Raimundo K.

J Rheumatol. 2018 Feb;45(2):235-241. doi: 10.3899/jrheum.170307. Epub 2017 Nov 15.

PMID:
29142033
21.

Idiopathic pulmonary fibrosis.

Martinez FJ, Collard HR, Pardo A, Raghu G, Richeldi L, Selman M, Swigris JJ, Taniguchi H, Wells AU.

Nat Rev Dis Primers. 2017 Oct 20;3:17074. doi: 10.1038/nrdp.2017.74. Review.

PMID:
29052582
22.

Looking ahead and behind at supplemental oxygen: A qualitative study of patients with pulmonary fibrosis.

Graney BA, Wamboldt FS, Baird S, Churney T, Fier K, Korn M, McCormick M, Vierzba T, Swigris JJ.

Heart Lung. 2017 Sep - Oct;46(5):387-393. doi: 10.1016/j.hrtlng.2017.07.001. Epub 2017 Jul 31.

PMID:
28774655
23.

Informal caregivers experience of supplemental oxygen in pulmonary fibrosis.

Graney BA, Wamboldt FS, Baird S, Churney T, Fier K, Korn M, McCormick M, Vierzba T, Swigris JJ.

Health Qual Life Outcomes. 2017 Jul 1;15(1):133. doi: 10.1186/s12955-017-0710-0.

24.

Supplemental Oxygen for Patients with Interstitial Lung Disease: Managing Expectations.

Swigris JJ.

Ann Am Thorac Soc. 2017 Jun;14(6):831-832. doi: 10.1513/AnnalsATS.201703-236ED. No abstract available.

PMID:
28570155
25.

Understanding the determinants of health-related quality of life in rheumatoid arthritis-associated interstitial lung disease.

Natalini JG, Swigris JJ, Morisset J, Elicker BM, Jones KD, Fischer A, Collard HR, Lee JS.

Respir Med. 2017 Jun;127:1-6. doi: 10.1016/j.rmed.2017.04.002. Epub 2017 Apr 5.

26.

High resolution computed tomography pattern of usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease: Relationship to survival.

Yunt ZX, Chung JH, Hobbs S, Fernandez-Perez ER, Olson AL, Huie TJ, Keith RC, Janssen WJ, Goldstein BL, Lynch DA, Brown KK, Swigris JJ, Solomon JJ.

Respir Med. 2017 May;126:100-104. doi: 10.1016/j.rmed.2017.03.027. Epub 2017 Mar 30.

PMID:
28427540
27.

Psychometric properties of the St George's Respiratory Questionnaire in patients with idiopathic pulmonary fibrosis.

Swigris JJ, Esser D, Wilson H, Conoscenti CS, Schmidt H, Stansen W, Leidy NK, Brown KK.

Eur Respir J. 2017 Jan 18;49(1). pii: 1601788. doi: 10.1183/13993003.01788-2016. Print 2017 Jan.

28.

Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis.

Nathan SD, Albera C, Bradford WZ, Costabel U, Glaspole I, Glassberg MK, Kardatzke DR, Daigl M, Kirchgaessler KU, Lancaster LH, Lederer DJ, Pereira CA, Swigris JJ, Valeyre D, Noble PW.

Lancet Respir Med. 2017 Jan;5(1):33-41. doi: 10.1016/S2213-2600(16)30326-5. Epub 2016 Nov 19. Erratum in: Lancet Respir Med. 2017 Jan;5(1):e7.

PMID:
27876247
29.

Clinical features and natural history of interstitial pneumonia with autoimmune features: A single center experience.

Chartrand S, Swigris JJ, Stanchev L, Lee JS, Brown KK, Fischer A.

Respir Med. 2016 Oct;119:150-154. doi: 10.1016/j.rmed.2016.09.002. Epub 2016 Sep 3.

30.

Plasma Leptin Is Elevated in Acute Exacerbation of Idiopathic Pulmonary Fibrosis.

Cao M, Swigris JJ, Wang X, Cao M, Qiu Y, Huang M, Xiao Y, Cai H.

Mediators Inflamm. 2016;2016:6940480. doi: 10.1155/2016/6940480. Epub 2016 Aug 25.

31.

Efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis with more preserved lung function.

Albera C, Costabel U, Fagan EA, Glassberg MK, Gorina E, Lancaster L, Lederer DJ, Nathan SD, Spirig D, Swigris JJ.

Eur Respir J. 2016 Sep;48(3):843-51. doi: 10.1183/13993003.01966-2015. Epub 2016 Jul 28.

32.

Idiopathic Pulmonary Fibrosis on the Internet. Let's Calm the Sea of (Mis)information.

Lederer DJ, Swigris JJ.

Am J Respir Crit Care Med. 2016 Jul 15;194(2):134-6. doi: 10.1164/rccm.201601-0190ED. No abstract available.

PMID:
27420357
33.

Understanding and optimizing health-related quality of life and physical functional capacity in idiopathic pulmonary fibrosis.

Olson AL, Brown KK, Swigris JJ.

Patient Relat Outcome Meas. 2016 May 17;7:29-35. doi: 10.2147/PROM.S74857. eCollection 2016. Review.

34.

What's it like to live with idiopathic pulmonary fibrosis? Ask the experts.

Russell AM, Swigris JJ.

Eur Respir J. 2016 May;47(5):1324-6. doi: 10.1183/13993003.00109-2016. No abstract available.

35.

Clinical Predictors of a Diagnosis of Common Variable Immunodeficiency-related Granulomatous-Lymphocytic Interstitial Lung Disease.

Mannina A, Chung JH, Swigris JJ, Solomon JJ, Huie TJ, Yunt ZX, Truong TQ, Brown KK, Achcar RD, Olson AL, Cox CW, Kligerman SJ, Curran-Everett D, Fernández Pérez ER.

Ann Am Thorac Soc. 2016 Jul;13(7):1042-9. doi: 10.1513/AnnalsATS.201511-728OC.

PMID:
27064856
36.

The Unmet Educational Needs of Patients with Interstitial Lung Disease. Setting the Stage for Tailored Pulmonary Rehabilitation.

Morisset J, Dubé BP, Garvey C, Bourbeau J, Collard HR, Swigris JJ, Lee JS.

Ann Am Thorac Soc. 2016 Jul;13(7):1026-33. doi: 10.1513/AnnalsATS.201512-836OC.

37.

Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis.

Nathan SD, Albera C, Bradford WZ, Costabel U, du Bois RM, Fagan EA, Fishman RS, Glaspole I, Glassberg MK, Glasscock KF, King TE Jr, Lancaster L, Lederer DJ, Lin Z, Pereira CA, Swigris JJ, Valeyre D, Noble PW, Wells AU.

Thorax. 2016 May;71(5):429-35. doi: 10.1136/thoraxjnl-2015-207011. Epub 2016 Mar 11.

38.

A Multidisciplinary Evaluation Helps Identify the Antisynthetase Syndrome in Patients Presenting as Idiopathic Interstitial Pneumonia.

Chartrand S, Swigris JJ, Peykova L, Chung J, Fischer A.

J Rheumatol. 2016 May;43(5):887-92. doi: 10.3899/jrheum.150966. Epub 2016 Mar 1.

PMID:
26932342
39.

Rituximab for the treatment of connective tissue disease-associated interstitial lung disease.

Chartrand S, Swigris JJ, Peykova L, Fischer A.

Sarcoidosis Vasc Diffuse Lung Dis. 2016 Jan 15;32(4):296-304.

PMID:
26847096
40.

Association Between Occupational Exposures and Sarcoidosis: An Analysis From Death Certificates in the United States, 1988-1999.

Liu H, Patel D, Welch AM, Wilson C, Mroz MM, Li L, Rose CS, Van Dyke M, Swigris JJ, Hamzeh N, Maier LA.

Chest. 2016 Aug;150(2):289-98. doi: 10.1016/j.chest.2016.01.020. Epub 2016 Jan 30.

41.

Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials.

Lancaster L, Albera C, Bradford WZ, Costabel U, du Bois RM, Fagan EA, Fishman RS, Glaspole I, Glassberg MK, King TE Jr, Lederer DJ, Lin Z, Nathan SD, Pereira CA, Swigris JJ, Valeyre D, Noble PW.

BMJ Open Respir Res. 2016 Jan 12;3(1):e000105. doi: 10.1136/bmjresp-2015-000105. eCollection 2016.

42.

Seeking and sharing: why the pulmonary fibrosis community engages the web 2.0 environment.

Albright K, Walker T, Baird S, Eres L, Farnsworth T, Fier K, Kervitsky D, Korn M, Lederer DJ, McCormick M, Steiner JF, Vierzba T, Wamboldt FS, Swigris JJ.

BMC Pulm Med. 2016 Jan 12;16:4. doi: 10.1186/s12890-016-0167-7.

43.

Clinical and economic burden of idiopathic pulmonary fibrosis: a retrospective cohort study.

Raimundo K, Chang E, Broder MS, Alexander K, Zazzali J, Swigris JJ.

BMC Pulm Med. 2016 Jan 5;16:2. doi: 10.1186/s12890-015-0165-1.

44.

Supplemental oxygen users with pulmonary fibrosis perceive greater dyspnea than oxygen non-users.

Cao M, Wamboldt FS, Brown KK, Hickman J, Olson AL, Solomon JJ, Swigris JJ.

Multidiscip Respir Med. 2015 Nov 30;10:37. doi: 10.1186/s40248-015-0035-y. eCollection 2015.

45.

Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials.

Noble PW, Albera C, Bradford WZ, Costabel U, du Bois RM, Fagan EA, Fishman RS, Glaspole I, Glassberg MK, Lancaster L, Lederer DJ, Leff JA, Nathan SD, Pereira CA, Swigris JJ, Valeyre D, King TE Jr.

Eur Respir J. 2016 Jan;47(1):243-53. doi: 10.1183/13993003.00026-2015. Epub 2015 Dec 2.

46.

Predictors of mortality in rheumatoid arthritis-associated interstitial lung disease.

Solomon JJ, Chung JH, Cosgrove GP, Demoruelle MK, Fernandez-Perez ER, Fischer A, Frankel SK, Hobbs SB, Huie TJ, Ketzer J, Mannina A, Olson AL, Russell G, Tsuchiya Y, Yunt ZX, Zelarney PT, Brown KK, Swigris JJ.

Eur Respir J. 2016 Feb;47(2):588-96. doi: 10.1183/13993003.00357-2015. Epub 2015 Nov 19.

47.

Patient Perspectives in OMERACT Provide an Anchor for Future Metric Development and Improved Approaches to Healthcare Delivery in Connective Tissue Disease Related Interstitial Lung Disease (CTD-ILD).

Mittoo S, Frankel S, LeSage D, Strand V, Shah AA, Christopher-Stine L, Danoff S, Hummers LK, Swigris JJ, Huscher D, Christensen AM, Cenac SL, Erbil JK, Ferguson S, Garcia-Valladares I, Grewal HK, Orbai AM, Smith KC, Tran M, Bingham CO 3rd, Castelino FV, Fischer A, Saketkoo LA.

Curr Respir Med Rev. 2015 Jun;11(2):175-183.

48.

The need for patient-centred clinical research in idiopathic pulmonary fibrosis.

Russell AM, Sprangers MA, Wibberley S, Snell N, Rose DM, Swigris JJ.

BMC Med. 2015 Sep 24;13:240. doi: 10.1186/s12916-015-0475-4.

49.

Development of ATAQ-LAM: a tool to assess quality of life in Lymphangioleiomyomatosis.

Walker TD, Desserich J, Albright K, Wamboldt FS, Belkin A, Fier K, Swigris JJ.

Health Qual Life Outcomes. 2015 Jul 30;13:112. doi: 10.1186/s12955-015-0294-5.

50.

An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune features.

Fischer A, Antoniou KM, Brown KK, Cadranel J, Corte TJ, du Bois RM, Lee JS, Leslie KO, Lynch DA, Matteson EL, Mosca M, Noth I, Richeldi L, Strek ME, Swigris JJ, Wells AU, West SG, Collard HR, Cottin V; “ERS/ATS Task Force on Undifferentiated Forms of CTD-ILD”.

Eur Respir J. 2015 Oct;46(4):976-87. doi: 10.1183/13993003.00150-2015. Epub 2015 Jul 9.

Supplemental Content

Loading ...
Support Center